12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Victrelis boceprevir regulatory update

FDA and EMA notified healthcare professionals and will update the U.S. and EU labels of Merck's HCV drug Victrelis boceprevir to include a warning of drug interactions with certain ritonavir-boosted HIV protease inhibitor drugs...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >